Of the 72 patient specimens with known MSI and BRAF status (MSS n = 30, MSI-H:BRAF mutant n = 19 and MSI-H:BRAF wild type n = 23), 19 patients from each subgroup were selected for analysis and of these 57 patients, 56 patient tumour specimens were analysed by CGE. Here, BRAF is linked to neoplasm.